UNSPSC 51111661: Troxacitabine

This classification denotes a pyrimidine antagonist with the molecular formula C8H11N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60KQZ0388Y, chemically known as 2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)- but generally known as troxacitabine, which bears US NIH Compound Identifier 151173. European Medicines Agency schedules Troxacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22612.

UNSPSC 51111661 Troxacitabine is a Commodity code identifying a specific chemotherapy agent, but the single recent state-local opportunity on record does not solicit troxacitabine itself. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a market-intelligence exercise seeking information about vendors' capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment and cost management. The RFI solicits vendor experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. This is an exploratory procurement mechanism designed to inform the state's future strategy rather than a formal competitive solicitation with binding timelines or award values.

The geographic scope of recent activity is limited to Texas. The single opportunity on record is an RFI issued by the Texas Health and Human Services Commission with a response deadline of April 3, 2026. Because the source shows no recent opportunities directly soliciting troxacitabine as a product line and the one identified RFI addresses a broader pharmacy benefit and contracting capacity question rather than a specific pharmaceutical procurement, the code shows little relevant recent activity in state and local procurement.